CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading researcher profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Researchers/Profile

Researcher profile

Dominic Oliver

OPENALEX: A5009227459↗ORCID: 0000-0002-8920-3407↗

Affiliations

Organizations

King's College Londonauthorship · GB King's College Schoolauthorship · GB National Institute for Health and Care Researchauthorship · GB Oxford BioMedica (United Kingdom)authorship · GB University of Oxfordauthorship · GB Warneford Hospitalauthorship · GB

Public evidence

9 connected articles

Acceptability of cannabidiol as a treatment for people at clinical high risk for psychosis2026 · medRxiv Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial.2025 · Europe PMC PSYSCAN multi-centre study: baseline characteristics and clinical outcomes of the clinical high risk for psychosis sample.2025 · Europe PMC Longitudinal evolution of the transdiagnostic prodrome to severe mental disorders: a dynamic temporal network analysis informed by natural language processing and electronic health records.2025 · Europe PMC Exploring the relationship between frequent cannabis use, belief updating under uncertainty and psychotic-like symptoms.2024 · Europe PMC Cannabidiol does not attenuate acute delta-9-tetrahydrocannabinol-induced attentional bias in healthy volunteers: A randomised, double-blind, cross-over study.2024 · Europe PMC Influence of cannabis use on incidence of psychosis in people at clinical high risk.2023 · Europe PMC Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios.2023 · Europe PMC Cannabidiol (CBD) as a novel treatment in the early phases of psychosis.2022 · Europe PMC

Registered research

Connected studies

Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Studynct04605393 Reducing the Harmful Effects of Cannabis Use: Finding the Optimal CBD:THC Rationct05170217

Matched by exact identifiers only. Profile data: Corpus/OpenAlex.

Dominic Oliver - Medical Cannabis Research Engine